Alerts will be sent to your verified email
Verify Email
CONCORD
|
Concord Drugs
|
Lasa Supergenerics
|
Biofil Chem & Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
3.38 % | -8.32 % | 5.42 % |
|
5yr average Equity Multiplier
|
1.86 | 1.44 | 2.09 |
|
5yr Average Asset Turnover Ratio
|
0.9 | 0.77 | 0.96 |
|
5yr Avg Net Profit Margin
|
1.88 % | -8.22 % | 2.86 % |
|
Price to Book
|
1.99 | 0.81 | 3.78 |
|
P/E
|
159.25 | 0.0 | 25.2 |
|
5yr Avg Cash Conversion Cycle
|
260.53 Days | 11.27 Days | 65.55 Days |
|
Inventory Days
|
138.17 Days | 46.83 Days | 25.38 Days |
|
Days Receivable
|
144.77 Days | 10.61 Days | 244.02 Days |
|
Days Payable
|
77.93 Days | 83.41 Days | 179.27 Days |
|
5yr Average Interest Coverage Ratio
|
1.8 | -18.91 | 21.93 |
|
5yr Avg ROCE
|
8.9 % | 1.03 % | 7.69 % |
|
5yr Avg Operating Profit Margin
|
9.09 % | 9.99 % | 4.5 % |
|
5 yr average Debt to Equity
|
0.55 | 0.2 | 0.04 |
|
5yr CAGR Net Profit
|
-21.63 % | n/a | -10.11 % |
|
5yr Average Return on Assets
|
1.77 % | -5.59 % | 2.72 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
54.39 % | 53.65 % | 46.82 % |
|
Share Pledged by Promoters
|
0.0 | 20.66 % | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
5.39 % | 9.87 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Concord Drugs
|
Lasa Supergenerics
|
Biofil Chem & Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
-
|
Product Wise Break-Up
|